Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

In early September 2025, Pfizer was trading in the mid–$20 range. After a relatively quiet first weeks of the month, the stock exploded higher at month-end. On Sept. 30, PFE closed at $25.48 after soaring ~6.8% that day investing.com. The rally continued on Oct. 1, with PFE closing at $27.21 investing.com. In total, Pfizer climbed roughly 15% in the five trading days Sept 26–Oct 1. By contrast, Pfizer had been about flat in August–September, hovering in the low $24s prior to this surge. The late-month gains reflect investor excitement over the Trump pricing deal and positive news on the pipeline.

Healthcare News · NYSE:PFE · Pharmaceutical Industry · Stock Market
Stocks Rally to Record Highs as Shutdown Looms – Dow and S&P Post Best September in 15 Years

Stocks Rally to Record Highs as Shutdown Looms – Dow and S&P Post Best September in 15 Years

U.S. stock markets closed Sept. 30 higher, ending the month on a positive note. The S&P 500 closed at 6,688.46, the Dow at 46,397.89, and the Nasdaq at 22,660.01 reuters.com. All three indices notched monthly and quarterly gains: for September, the S&P rose about 3.5% reuters.com reuters.com, and the Dow and Nasdaq each notched their largest one-month rise since 2019. This pushed the Dow to another record closing high reuters.com. Defensive sectors outperformed, while cyclical areas lagged due to shutdown risks.
1 October 2025
··
Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

“TrumpRx” is a planned federal website that will let Americans buy prescription medicines directly from the government at cash prices. According to administration officials, TrumpRx will negotiate discounted rates with drugmakers and allow patients to pay out-of-pocket for certain drugs, bypassing insurers and middlemen wbtv.com reuters.com. White House Press Secretary Karoline Leavitt confirmed on social media that Trump will announce TrumpRx, and a Wall Street Journal report says the site will be branded TrumpRx newsweek.com reuters.com. It is not yet clear which medications will be offered, but the idea is to force prices lower by having the government bulk-buy like a pharmacy. In effect, TrumpRx revives a concept from his first term but goes further by having the government directly sell drugs.
30 September 2025
·
Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

Pfizer (PFE) Stock Soars on Trump’s Drug-Price Pact and $7.3B Weight-Loss Deal

On Sept 30, 2025 Pfizer closed around $24.40 reuters.com. Over the past year PFE underperformed the pharma sector. Its trailing P/E is 12.64× reuters.com and forward P/E ~7.7× reuters.com, compared to ~19× for J&J and ~12× for Merck. Pfizer’s dividend yield reuters.com is by far the highest in big pharma. The stock rallied on strong earnings in early August s206.q4cdn.com reuters.com and on the Sept 30 Trump pricing news.
30 September 2025
··
Nasdaq’s Wild Week: AI Mega-Deal Hype, Tariff Turmoil, and Tech Titans on Edge

Nasdaq’s Wild Week: AI Mega-Deal Hype, Tariff Turmoil, and Tech Titans on Edge

After charging to all-time highs on Monday, U.S. tech stocks hit some turbulence to end the week. The Nasdaq Composite Index gained +0.44% on Friday to close around 22,484 reuters.com, helped by a relief rally on in-line inflation data. That advance broke a three-day losing streak for stocks latimes.com. Even so, the Nasdaq Composite fell ~0.7% for the week, while the S&P 500 and Dow also logged modest weekly declines reuters.com reuters.com. This marked the end of a three-week run of gains for the Nasdaq and S&P reuters.com. The Nasdaq-100 index of top-tier tech shares showed a similar pattern – rebounding Friday but finishing slightly lower week-over-week.
27 September 2025
··········
Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer’s stock has struggled in 2025, hovering near multi-year lows. At ~$23.60 per share in late September, PFE has declined about 9% since January, underperforming the S&P 500 and lagging the broader healthcare sector. Over the past 12 months, the stock is down roughly 18%. The 52-week high was $30.43, and shares now sit not far above their year’s low of $20.92 stockanalysis.com. By market capitalization, Pfizer remains one of the world’s largest pharmaceutical companies, but its valuation has compressed significantly from pandemic-era peaks.
26 September 2025
···
Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

Sources: Key information and quotes in this report are sourced from recent Reuters news dispatches, official press releases, and expert commentary in credible outlets. For full details and further reading, please see the linked sources reuters.com reuters.com reuters.com reuters.com abcnews.go.com abcnews.go.com reuters.com reuters.com sciencedaily.com sciencedaily.com fiercehealthcare.com techstartups.com, among others. Each link corresponds to the original announcement or publication reporting the development in question. This roundup captures the major biotech, pharmaceutical, medical, and health news from August 17–18, 2025, highlighting the continuing innovations and challenges in the health sciences world. Let’s stay tuned as these stories evolve.
18 August 2025
·····
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

For the period August 15–16, 2025, the biotech, pharma, medical, and health sectors saw a flurry of significant developments worldwide. Here is a comprehensive roundup of the top stories, categorized by theme and featuring expert insights and source links:
16 August 2025
··········
Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

This weekend brought a flurry of significant biotech, pharmaceutical, medical, and health developments worldwide – from game-changing scientific breakthroughs to high-stakes regulatory decisions and industry shake-ups. Below is a comprehensive roundup of the major news from August 9 and 10, 2025, organized by category for easy reading.
10 August 2025
······
Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Biotechnology is at the forefront of scientific innovation in 2025, driven by companies around the world that are transforming healthcare, agriculture, and industry. This report profiles 100 of the most important global biotechnology companies selected for their global impact, innovation, revenue, scientific breakthroughs, and sector influence. These companies span biopharmaceutical giants, genomics and diagnostics pioneers, agricultural and environmental biotech leaders, industrial biotech innovators, and key providers of biotech tools and services. Each entry includes the company’s headquarters country, primary sector, notable contributions or innovations, and a link to its official website. The list encompasses both publicly traded and private firms, reflecting the worldwide landscape of biotech innovation.
22 June 2025
···········
1 … 10 11 12
Follow on Google News
Add as preferred source Open in Google News